Protective effect of systemic l-kynurenine and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid beta (25-35) in rat hippocampus

Behavioural Brain Research

Volumn 210, Issue 2, 2010, Pages 240-250

  Carrillo Mora, Paul ^a   Méndez Cuesta, Luis A ^a   Pérez De La Cruz, Verónica ^a   Fortoul van Der Goes, Teresa I ^b   Santamaría, Abel ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Amyloid beta toxicity; Hippocampus; Kynurenines; Morphological alterations; Probenecid; Spatial memory

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; DIZOCILPINE; KYNURENINE; PROBENECID;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL DAMAGE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG MECHANISM; EXCITOTOXICITY; GLIOSIS; HIPPOCAMPUS; INTRAHIPPOCAMPAL DRUG ADMINISTRATION; LOCOMOTION; LOW DRUG DOSE; MALE; MOTOR PERFORMANCE; NEUROANATOMY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL MEMORY; SYSTEMIC THERAPY; TREATMENT DURATION;

AMYLOID BETA-PROTEIN; ANIMALS; BEHAVIOR, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; KYNURENINE; MALE; MAZE LEARNING; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PROBENECID; RATS; RATS, WISTAR; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 77952321612     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.02.041     Document Type: Article

References (93)

1. Ahlander M., Misane I., Schott P.A., Ogren S.O. A behavioral analysis of the spatial learning deficit induced by the NMDA receptor antagonist MK-801 (dizocilpine) in the rat. Neuropsychopharmacology 1999, 21:414-426.
2. Alkondon M., Pereira E.F.R., Yu P., Arruda E.Z., Almeida L.E.F., Guidetti P., et al. Targeted deletion of the kynurenine aminotransferase II gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via α7 nicotinic receptors in the hippocampus. J Neurosci 2004, 24(19):4635-4648.
3. Atwood C.S., Obrenovich M.E., Liu T., Chan H., Perry G., Smith M.A., et al. Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid β. Brain Res Rev 2003, 43:1-16.
4. Baran H., Jellinger H., Deecke L. Kynurenine metabolism in Alzheimer's disease. J Neural Transm 1999, 106:165-181.
5. Butterfield D.A., Reed T., Newman S.F., Sultana R. Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Rad Biol Med 2007, 43:658-677.
6. Canevari L., Clark J.B., Bates T.E. β-amyloid fragment 25-35 selectively descreases complex IV activity in isolated mitochondria. FEBS Lett 1999, 457:131-134.
7. Carrillo-Mora P., Giordano M., Santamaría A. Spatial memory: theoretical basis and comparative review on experimental methods in rodents. Behav Brain Res 2009, 203:151-164.
8. Carter A.J. Many agents that antagonize the NMDA receptor-channel complex in vivo also cause disturbance of motor coordination. J Phramacol Exp Ther 1994, 269:573-580.
9. Carter A.J. Glycine antagonists: regulation of the NMDA receptor-channel complex by the strychnine-insensitive glycine site. Drugs Future 1992, 17:595-613.
10. Chen S.Y., Wrigth J.W., Barnes C.D. The neurochemical and behavioral effects of β-amyloid peptide (25-35). Brain Res 1996, 720:54-60.
11. Chen Y.H., Wu M.L., Fu W.M. Regulation of presynaptic NMDA responses by external and intracellular pH changes at developing neuromuscular synapses. J Neurosci 1998, 18:2982-2990.
12. Chess A.C., Simoni M.K., Alling T.E., Bucci D.J. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 2007, 33:797-804.
13. Cummings J.L. Alzheimer's disease. N Engl J Med 2004, 351:56-67.
14. D'Hooge R., De Deyn P.P. Applications of the Morris water maze in the study of learning and memory. Brain Res Rev 2001, 36:60-90.
15. Drachman D.A. Aging of the brain, entropy and Alzheimer disease. Neurology 2006, 67:1340-1352.
16. Eckman C.B., Eckman E.A. An update on the amyloid hypothesis. Neurol Clin 2007, 25:669-682.
17. Farber J.L., Chien K.R., Mittnacht S. The pathogenesis of irreversible cell injury in ischemia. Am J Pathol 1981, 102:271-281.
18. Farber J.L. Biology of disease: membrane injury and calcium homeostasis in the pathogenesis of coagulation necrosis. Lab Invest 1982, 47:114-123.
19. Farlow M.R., Cumming J.L. Effective pharmacologic management of Alzheimer's disease. Am J Med 2007, 120:388-397.
20. Fatokun A.A., Smith R.A., Stone T.W. Resistance to kynurenic acid of the NMDA receptor-dependent toxicity of 3-nitropropionic acid and cyanide in cerebellar granule neurons. Brain Res 2008, 1215:200-207.
21. Fitzjohn S.M., Morton R.A., Kuenzi F., Rosahl T.W., Shearman M., Lewis H., et al. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J Neurosci 2001, 21:4691-4698.
22. Ford L.M., Norman A.B., Sanberg P.R. The topography of MK-801-induced locomotor patterns in rats. Physiol Behav 1989, 46:755-758.
23. Gamache D.A., Ellis E.F. Effect of dexamethasone, indomethacin, ibuprofen, and probenecid on carrageenan-induced brain inflammation. J Neurosurg 1986, 65:686-692.
24. Garcia J.H., Liu K.F., Ho K.L. Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progress at different time intervals in the caudo-putamen and the cortex. Stroke 1995, 26:636-642.
25. Gigler G., Szenasi G., Simo A., Levay G., Harsing L.G., Sas K., et al. Neuroprotective effect of l-KYNurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur J Pharmacol 2007, 564:116-122.
26. Goda K, Hamane Y, Kishimoto R, Ogishi Y. Radical scavenging of tryptophan metabolites: Estimation of their radical reactivity. Content in: Huether G, Kochen W, Simat TJ, Steinhart H, editors. Advances in experimental medicine and biology: tryptophan, serotonin and melatonin. Basic aspects and applications. New York: Kluwer Academic/Plenum Publishers; 1999.
27. Guillemin G.J., Brew B.J., Noonan C.E., Takikawa O., Cullen K.M. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol 2005, 31:395-404.
28. Guillemin G.J., Smythe G.A., Veas L.A., Takikawa O., Brew B.J. A beta 1-42 induces production of quinolinic acid by human macrophages and microglia. NeuroReport 2003, 14:2311-2315.
29. Guillemin G.J., Smith D.G., Williams K., Smythe G.A., Dormont D., Brew B.J. b-Amyloid peptide 1-42 induces human macrophages to produce the neurotoxin quinolinic acid. J Neuroimmunol 2001, 118:336.
30. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharm Sci 1991, 12:383-388.
31. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
32. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 286:184-185.
33. Harkany T., Abraham I., Timmerman W., Laskay G., Toth B., Sasvari M., et al. Beta-amyloid neurotoxicity is mediated by a glutamate triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 2000, 12:735-2745.
34. Hartai Z., Juhász A., Rimanóczy A., Janáky T., Donkó T., Dux L., et al. Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease. Neurochem Int 2007, 50:308-313.
35. Hesselink M.B., Smolders H., Eilbacher B., De Boer A.G., Breimer D.D., Danysz W. The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-d-aspartate receptor antagonists acting at the glycineB-site: microdialysis and maximum electroshock seizures studies. J Pharmacol Exp Ther 1999, 290:543-550.
36. Hlinak Z., Krejci I. Spontaneous alternation behaviour in rats: kynurenic acid attenuated deficits induced by MK-801. Behav Brain Res 2006, 168:144-149.
37. Holscher C., Gengler S., Gault V.A., Harriott P., Mallot H.A. Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur J Pharmacol 2007, 561:85-90.
38. Hynd M.R., Scott H.L., Dodd P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004, 45:583-595.
39. Ikonomidou C., Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?. Lancet Neurol 2002, 1:383-386.
40. Institute of Laboratory Animal Resources. Commission of Life Sciences. National Research Council. Guide for the care and use of laboratory animals. Washington, D.C.: National Academy Press; 1996.
41. Irie K., Murakami K., Masuda Y., Morimoto A., Ohigashi H., Ohashi R., et al. Structure of β-amyloid fibrils and its relevance to their neurotoxicity: implications for the pathogenesis of Alzheimer's disease. J Biosci Bioeng 2005, 99:437-447.
42. Irifune M., Shimizu T., Nomoto M., Fukuda T. Involvement of N-methyl-d-aspartate (NMDA) receptors in noncompetitive NMDA receptor antagonist-induced hyperlocomotion in mice. Pharmacol Biochem Behav 1995, 51:291-296.
43. Joshi S., Morley J.E. Cognitive impairment. Med Clin North Am 2006, 90:769-787.
44. Kemp J.A., McKernan R.M. NMDA receptor pathways as drug targets. Nature Neurosci 2002, (Suppl. 5):1039-1042.
45. Kimelberg H.K. The problem of astrocyte identity. Neurochem Int 2004, 45:191-202.
46. Kiyota Y., Miyamoto M., Nagaoka A. Relationship between brain damage and memory impairment in rats exposed to transient forebrain ischemia. Brain Res 1991, 538:295-302.
47. Koek W., Colpaert F.C. Selective blockade of N-methyl-d-aspartate (NMDA)-induced convulsions by NMDA antagonist and putative glycine antagonist: relationships with phencyclidine-like behavioral effects. J Pharmacol Exp Ther 1990, 252:349-357.
48. Kowall N.W., McKee A.C., Yankner B.A., Beal M.F. In vivo neurotoxicity of beta amyloid [β(1-40)] and the β(25-35) fragment. Neurobiol Aging 1992, 13:537-542.
49. Lederer R., Radeke E., Mondadori C. Facilitation of social learning by treatment with an NMDA receptor antagonist. Behav Neural Biol 1993, 60:220-224.
50. Leeson P.D., Iversen L.L. The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. Med Chem 1994, 37:4053-4067.
51. Lin H., Bhatia R., Lal R. Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J 2001, 15:2433-2444.
52. Lipton S.A. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 2004, 1:101-110.
53. McDonald J.W., Silverstein F.S., Johnston M.V. Neuroprotective effects of MK-801, TCP, PCP and CPP against N-methyl-o-aspartate induced neurotoxicity in an in vivo perinatal rat model. Brain Res 1989, 490:33-40.
54. Miller J., MacGarvey U., Beal M.F. The effect of peripheral loading with kynurenine and probenecid on extracellular striatal kynurenic acid concentrations. Neurosci Lett 1992, 146:115-118.
55. Miranda A.F., Boegman R.J., Beninger R.J., Jhamandas K. Protection against quinolinc acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience 1997, 78:967-975.
56. Mok M.H.S., Fricker A.C., Weil A., Kew J.N.C. Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels. Neuropharmacology 2009, 10.1016/j.neuropharm.2009.06.003.
57. Mondadori C., Weiskrantz L., Buerki H., Petschke F., Fragg G.E. NMDA receptor antagonist can enhance or impair learning performance in animals. Exp Brain Res 1989, 75:449-456.
58. Muir K.W., Lees K.R. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995, 26:503-513.
59. Muir K.W. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 2006, 6:53-60.
60. Nagele R.G., D'Andrea M.R., Anderson W.J., Wang H.Y. Intracellular accumulation of beta amyloid (1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 2002, 110:199-211.
61. Norton W.T., Aquino D.A., Hozumi I., Chiu F.C., Brosnan C.F. Cuantitative aspects of reactive Gliosis. Neurochem Res 1992, 17:877-885.
62. Pakaski M., Kalman J. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neurochem Int 2008, 53:103-111.
63. Parameshwaran K., Dhanasekaran M., Suppiramaniam V. Amyloid beta peptides and glutamatergic synaptic dysregulation. Exp Neurol 2008, 210:7-13.
64. Parsons C.G., Stoffler A., Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 2007, 53:699-723.
65. Paxinos G., Watson G. The rat brain in stereotaxic coordinates 1986, Academic Press, USA.
66. Pérez-Severiano F., Salvatierra-Sánchez R., Rodríguez-Pérez M., Cuevas-Martínez E.Y., Guevara J., Limón D., et al. S-Allylcysteine prevents amyloid-beta peptide-induced oxidative stress in rat hippocampus and ameliorates learning deficits. Eur J Pharmacol 2004, 489:197-202.
67. Poeggeler B., Reiter R.J., Hardeland R., Tan D.X., Barlow-Walden L.R. Melatonin and structurally-related endogenous indoles acts as potent electron donors and radical scavengers in vitro. Redox Rep 1996, 2:179-184.
68. Raffi M.S., Aisen P.S. Recent developments in Alzheimer's disease therapeutics. BMC Med 2009, 7:7-10.
69. Rahman A., Ting K., Cullen K.M., Braidy N., Brew B.J., Guillermin G.J. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PloS ONE 2009, 4:1-15.
70. Riedel G., Platt B., Micheau J. Glutamate receptor function in learning and memory. Behav Brain Res 2003, 140:1-47.
71. Robotka H., Sas K., Agoston M., Rozsa E., Szenasi G., Gigler G., et al. Neuroprotection achieved in the ischaemic rat cortex with l-kynurenine sulphate. Life Sci 2008, 82:915-919.
72. Rosales-Corral S., Tan D.X., Reiter R.J., Valdivia-Velazquez M., Acosta-Martinez J.P., Ortiz G.G. Kinetics of the neuroinflammation-oxidative stress correlation in rat brain following the injection of fibrillar amyloid-β onto the hippocampus in vivo. J Neuroimmunol 2004, 150:20-28.
73. Santamaría A., Rios C., Solis-Hernandez F., Ordaz-Moreno J., González-Reynoso S., Altagracia M., et al. Systemic dl-KYNurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats. Neuropharmacology 1996, 35:23-28.
74. Sas K., Robotka H., Rozsa E., Agoston M., Szenasi G., Gigler G., et al. Kynurenine diminishes the ischemia-induced histological and electrophysiological deficits in the rat hippocampus. Neurobiol Dis 2008, 32:302-308.
75. Schmid A.W., Freir D.A., Herron C.E. Inhibition of LTP in vivo by beta-amyloid peptide in different conformational states. Brain Res 2008, 1197:135-142.
76. Schwarcz R., Pellicciari R. Manipulation of brain kynurenines: Glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 2002, 303:1-10.
77. Silva-Adaya D., Pérez-De La Cruz V., Herrera-Mundo M.N., Mendoza-Macedo K., Villeda-Hernández J., Binienda Z., et al. Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects. J Neurochem 2008, 105:677-689.
78. Silverman W., Locovei S., Dahl G. Probenecid, a gout remedy, inhibits pannexin 1 channels. Am J Physiol Cell Physiol 2008, 295:C761-C767.
79. Smith M.A., Casadesus G., Joseph J.A., Perry G. Amyloid β and τ serve antioxidant functions in the aging and Alzheimer brain. Free Rad Biol Med 2002, 33:1194-1199.
80. Stepanichev M.Y., Zdobnova I.M., Zarubenko I.I., Moiseeva Y.V., Lazareva N.A., Onufriev M.V., et al. Amyloid-β(25-35)-induced memory impairments correlate with cell loss in rat hippocampus. Physiol Behav 2004, 80:647-655.
81. Stone T.W. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci 2000, 21:149-154.
82. Stone T.W. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog Neurobiol 2001, 64:185-218.
83. Tohda C., Tamura T., Komatsu K. Repair of amyloid beta (25-35)-induced memory impairment and synaptic loss by a Kampo formula, Zokumei-to. Brain Res 2003, 990:141-147.
84. Trump B.F., Berezesky I.K., Sato T., Laiho K.U., Phelps P.C., DeClaris N. Cell calcium, cell injury and cell death. Environ Health Perspect 1984, 57:281-287.
85. Vecsei L., Beal F. Intracerebroventricular injection of kynurenic acid, but not kynurenine, induces ataxia and stereotyped behaviour in rats. Brain Res Bull 1990, 25:623-627.
86. Vecsei L., Miller J., MacGarvey U., Beal M.F. Kynurenine and probenecid inhibit pentylentetrazol- and NMDLA-induced seizures and increases kynurenic acid concentrations in the brain. Brain Res Bull 1992, 28:233-238.
87. Vetrivel K.S., Thinakaran G. Amyloidogenic processing of β-amyloid precursor protein in intracellular compartments. Neurology 2006, 66(Suppl. 1):S69-S73.
88. Wenk G.L., Parsons C.G., Danysz W. Potential role of N-methyl-d-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol 2006, 17:411-424.
89. Widner B., Leblhuber F., Walli J., Tilz G.P., Demel U., Fuchs D. Degradation of tryptophan in neurodegenerative disorders. Adv Exp Med Biol 1999, 467:133-138.
90. Wozniak D.F., Olney J.W., Kettinger L., Price M., Miller J.P. Behavioral effects of MK-801 in the rat. Psychopharmacol 1990, 101:47-56.
91. Yamada A., Akimoto H., Kagawa S., Guillemin G.J., Takikawa O. Proinflammatory cytokine interferon-gamma increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease. J Neurochem 2009, 110:791-800.
92. Yankner B.A., Duffy L.K., Krischner D.A. Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 1990, 250:279-282.
93. Zoladz P.R., Campbell A.M., Park C.R., Schaefer D., Danysz W., Diamond D.M. Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. Pharmacol Biochem Behav 2006, 85:298-306.